Scientist II, Drug Product

About the role

Revolution Medicines is seeking Scientist II to join the Drug Product team within Pharmaceutical Development & Manufacturing (PDM). This role will support the development of solid oral dosage forms for small molecule programs across the RVMD pipeline. The successful candidate will contribute to formulation and process development activities from early-stage through late-stage clinical/commercial development, working closely with cross-functional partners and CDMOs to ensure robust, scalable, and compliant drug product manufacturing processes.

Responsibilities

• Contribute to drug product development activities for new chemical entities (NCEs) from early development through late-stage clinical development, with exposure to commercialization activities.
• Design and execute drug product development and manufacturing activities for solid oral dosage forms, including:
• Preformulation and formulation development.
• Manufacturing process development.
• Process scale-up, technology transfer, and process optimization.
• Process validation and commercial manufacturing support.
• Support outsourced development and GMP drug product manufacturing activities at CDMOs including manufacturing oversight and troubleshooting.
• Design and execute experiments, analyze and interpret data and present results and conclusions to project teams.
• Work independently with limited supervision to conduct appropriate research and troubleshoot technical challenges, escalating complex issues as needed.
• Author and contribute to CMC documentation for regulatory submissions (e.g., INDs, NDAs, MAAs) and internal technical reports.
• Collaborate cross-functionally within CMC team (Clinical Supply, Analytical Development/QC, Quality Assurance, Drug Substance, Regulatory Affairs, and Project Management) and at enterprise level research/clinical/commercial teams to support aligned development strategy and execution.
• Travel up to 20% to CRO/CDMO sites to support and oversee development and manufacturing operations.
• Required Skills, Experience and Education:
• A degree in Pharmaceutical Science, Chemistry, Chemical Engineering, or closely related field is desirable.
• Ph.D. with minimum of 3+ years of experience or a bachelor's/master's degree with appropriate experience in the pharmaceutical/biotech industry settings.
• Experience supporting drug product development and manufacturing for small molecules.
• Demonstrated experience in solid oral dosage formulation and process development for small molecules.
• Experience working with external partners (CDMOs/CROs) and overseeing outsourced development and manufacturing activities.
• Working knowledge of global regulatory expectations, including ICH guidelines and FDA, EMA, PMDA etc. requirements.
• Experience contributing to CMC regulatory filings is desirable.
• Strong technical writing, communication, and problem-solving skills.
• Ability to manage multiple priorities and thrive in a fast-paced, innovation-driven collaborative environment.
• Preferred Skills:
• Ph.D. degree in Pharmaceutical Science, Chemistry, Chemical Engineering, or closely related field is desirable.
• #LI-Hybrid #LI-CT1
• Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
• Revolution Medicines is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital status, medical condition, an

Benefits

Additional Information

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

Your Match

How well this role fits your profile.

Company Intel

What employees say

Worked at revolutionmedicines? Share your experience